{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T11:59:26Z","timestamp":1761393566840},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2007,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background\/Aim<\/jats:title>\n            <jats:p>The role of humoral immunity in hepatitis C virus (HCV) infection is poorly understood. Nevertheless, there is increasing interest in characterizing the neutralizing antibodies in the serum of HCV-infected patients. Focus reduction assays have been widely used to evaluate neutralizing antibody responses against a range of non-cytopathic viruses. Based on the recent development of a HCV cell culture system using the genotype 2 JFH-1-strain, we developed a focus reduction assay for HCV-neutralizing antibodies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The focus reduction assay was based on a standard microneutralization assay in which immunostained foci on tissue culture plates are counted. The neutralizing anti-HCV antibodies titers of purified serum immunoglobulin samples from seventy-seven individuals were determined using a 50% focus reduction neutralization assay. Each titer was determined as the log value of the reciprocal antibody dilution that reduced the number of viral foci by 50%. IgG antibodies were first purified from each serum in order to avoid the facilitating effect of HDL on HCV entry.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The assay's cut-off using an ELISA and RNA HCV-negative samples was found to be 1.25 log, corresponding to a dilution of 1:18. The assay was compared with a commercial HCV ELISA and exhibited specificity and sensitivity values of 100% and 96.5%, respectively, and good reproducibility (with intra-assay and inter-assay coefficients of variation of 6.7% and 12.6%, respectively). The assay did not show any cross-reactivity with anti-HIV, anti-HBs or heterophile antibody-positive samples. The neutralizing antibodies titers were 2.13 log (1:134) for homologous samples from HCV genotype 2 infected patients harboring the same genotype as JFH-1 and 1.93 log (1:85) for heterologous samples from patients infected by genotypes other than type 2. These results confirm the presence of broadly cross-neutralizing antibodies already reported using the HCV pseudoparticles system.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This study presents a simple, specific and reproducible cell culture-based assay for determination of HCV-neutralizing antibodies in human sera. The assay should be an important tool for gauging the relationship between the neutralizing antibodies response and viral load kinetics in acutely or chronically infected patients and for investigating the possible eradication or prevention of HCV infection by neutralizing antibodies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1743-422x-4-35","type":"journal-article","created":{"date-parts":[[2007,5,2]],"date-time":"2007-05-02T15:39:20Z","timestamp":1178120360000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies"],"prefix":"10.1186","volume":"4","author":[{"given":"Carole","family":"Fournier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Duverlie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Fran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurelie","family":"Schnuriger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Dedeurwaerder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etienne","family":"Brochot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Capron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Czeslaw","family":"Wychowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Castelain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,3,30]]},"reference":[{"key":"248_CR1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJM200107053450107","volume":"345","author":"GM Lauer","year":"2001","unstructured":"Lauer GM, Walker BD: Hepatitis C virus infection. N Engl J Med 2001, 345: 41-52. 10.1056\/NEJM200107053450107","journal-title":"N Engl J Med"},{"key":"248_CR2","doi-asserted-by":"publisher","first-page":"10149","DOI":"10.1073\/pnas.0403519101","volume":"101","author":"C Logvinoff","year":"2004","unstructured":"Logvinoff C, Major ME, Oldach D, Heyward S, Talal A, Balfe P, Feinstone SM, Alter H, Rice CM, McKeating JA: Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci USA 2004, 101: 10149-10154. 10.1073\/pnas.0403519101","journal-title":"Proc Natl Acad Sci USA"},{"key":"248_CR3","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1128\/JVI.78.1.187-196.2004","volume":"78","author":"C Rollier","year":"2004","unstructured":"Rollier C, Depla E, Drexhage JA, Verschoor EJ, Verstrepen BE, Fatmi A, Brinster C, Fournillier A, Whelan JA, Whelan M, et al.: Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral Thelper immune response. J Virol 2004, 78: 187-196. 10.1128\/JVI.78.1.187-196.2004","journal-title":"J Virol"},{"key":"248_CR4","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1055\/s-2000-9947","volume":"20","author":"M Lechmann","year":"2000","unstructured":"Lechmann M, Liang TJ: Vaccine development for hepatitis C. Semin Liver Dis 2000, 20: 211-226. 10.1055\/s-2000-9947","journal-title":"Semin Liver Dis"},{"key":"248_CR5","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1099\/0022-1317-82-8-1877","volume":"82","author":"A Owsianka","year":"2001","unstructured":"Owsianka A, Clayton RF, Loomis-Price LD, McKeating JA, Patel AH: Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. J Gen Virol 2001, 82: 1877-1883.","journal-title":"J Gen Virol"},{"key":"248_CR6","doi-asserted-by":"crossref","first-page":"6235","DOI":"10.1128\/JVI.73.8.6235-6244.1999","volume":"73","author":"M Flint","year":"1999","unstructured":"Flint M, Maidens C, Loomis-Price LD, Shotton C, Dubuisson J, Monk P, Higginbottom A, Levy S, McKeating JA: Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J Virol 1999, 73: 6235-6244.","journal-title":"J Virol"},{"key":"248_CR7","doi-asserted-by":"publisher","first-page":"10407","DOI":"10.1128\/JVI.74.22.10407-10416.2000","volume":"74","author":"KG Hadlock","year":"2000","unstructured":"Hadlock KG, Lanford RE, Perkins S, Rowe J, Yang Q, Levy S, Pileri P, Abrignani S, Foung SK: Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J Virol 2000, 74: 10407-10416. 10.1128\/JVI.74.22.10407-10416.2000","journal-title":"J Virol"},{"key":"248_CR8","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1099\/0022-1317-81-10-2451","volume":"81","author":"T Allander","year":"2000","unstructured":"Allander T, Drakenberg K, Beyene A, Rosa D, Abrignani S, Houghton M, Widell A, Grillner L, Persson MA: Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81. J Gen Virol 2000, 81: 2451-2459.","journal-title":"J Gen Virol"},{"key":"248_CR9","doi-asserted-by":"publisher","first-page":"7792","DOI":"10.1073\/pnas.91.16.7792","volume":"91","author":"P Farci","year":"1994","unstructured":"Farci P, Alter HJ, Wong DC, Miller RH, Govindarajan S, Engle R, Shapiro M, Purcell RH: Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci USA 1994, 91: 7792-7796. 10.1073\/pnas.91.16.7792","journal-title":"Proc Natl Acad Sci USA"},{"key":"248_CR10","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1128\/jvi.68.3.1494-1500.1994","volume":"68","author":"YK Shimizu","year":"1994","unstructured":"Shimizu YK, Hijikata M, Iwamoto A, Alter HJ, Purcell RH, Yoshikura H: Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J Virol 1994, 68: 1494-1500.","journal-title":"J Virol"},{"key":"248_CR11","doi-asserted-by":"publisher","first-page":"8217","DOI":"10.1128\/JVI.79.13.8217-8229.2005","volume":"79","author":"B Bartosch","year":"2005","unstructured":"Bartosch B, Verney G, Dreux M, Donot P, Morice Y, Penin F, Pawlotsky JM, Lavillette D, Cosset FL: An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J Virol 2005, 79: 8217-8229. 10.1128\/JVI.79.13.8217-8229.2005","journal-title":"J Virol"},{"key":"248_CR12","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1126\/science.282.5390.938","volume":"282","author":"P Pileri","year":"1998","unstructured":"Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G, Abrignani S: Binding of hepatitis C virus to CD81. Science 1998, 282: 938-941. 10.1126\/science.282.5390.938","journal-title":"Science"},{"key":"248_CR13","doi-asserted-by":"publisher","first-page":"6023","DOI":"10.1128\/JVI.79.10.6023-6034.2005","volume":"79","author":"D Lavillette","year":"2005","unstructured":"Lavillette D, Morice Y, Germanidis G, Donot P, Soulier A, Pagkalos E, Sakellariou G, Intrator L, Bartosch B, Pawlotsky JM, Cosset FL: Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol 2005, 79: 6023-6034. 10.1128\/JVI.79.10.6023-6034.2005","journal-title":"J Virol"},{"key":"248_CR14","doi-asserted-by":"publisher","first-page":"14199","DOI":"10.1073\/pnas.2335981100","volume":"100","author":"B Bartosch","year":"2003","unstructured":"Bartosch B, Bukh J, Meunier JC, Granier C, Engle RE, Blackwelder WC, Emerson SU, Cosset FL, Purcell RH: In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci USA 2003, 100: 14199-14204. 10.1073\/pnas.2335981100","journal-title":"Proc Natl Acad Sci USA"},{"key":"248_CR15","doi-asserted-by":"publisher","first-page":"4560","DOI":"10.1073\/pnas.0501275102","volume":"102","author":"JC Meunier","year":"2005","unstructured":"Meunier JC, Engle RE, Faulk K, Zhao M, Bartosch B, Alter H, Emerson SU, Cosset FL, Purcell RH, Bukh J: Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc Natl Acad Sci USA 2005, 102: 4560-4565. 10.1073\/pnas.0501275102","journal-title":"Proc Natl Acad Sci USA"},{"key":"248_CR16","doi-asserted-by":"publisher","first-page":"7793","DOI":"10.1074\/jbc.M411600200","volume":"280","author":"C Voisset","year":"2005","unstructured":"Voisset C, Callens N, Blanchard E, Op De Beeck A, Dubuisson J, Vu-Dac N: High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. J Biol Chem 2005, 280: 7793-7799. 10.1074\/jbc.M411600200","journal-title":"J Biol Chem"},{"key":"248_CR17","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/nm1268","volume":"11","author":"T Wakita","year":"2005","unstructured":"Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krausslich HG, Mizokami M, et al.: Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005, 11: 791-796. 10.1038\/nm1268","journal-title":"Nat Med"},{"key":"248_CR18","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1126\/science.1114016","volume":"309","author":"BD Lindenbach","year":"2005","unstructured":"Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM: Complete replication of hepatitis C virus in cell culture. Science 2005, 309: 623-626. 10.1126\/science.1114016","journal-title":"Science"},{"key":"248_CR19","doi-asserted-by":"publisher","first-page":"9294","DOI":"10.1073\/pnas.0503596102","volume":"102","author":"J Zhong","year":"2005","unstructured":"Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T, Chisari FV: Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 2005, 102: 9294-9299. 10.1073\/pnas.0503596102","journal-title":"Proc Natl Acad Sci USA"},{"key":"248_CR20","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1099\/vir.0.81932-0","volume":"87","author":"C Voisset","year":"2006","unstructured":"Voisset C, de Beeck AO, Horellou P, Dreux M, Gustot T, Duverlie G, Cosset FL, Vu-Dac N, Dubuisson J: High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry. J Gen Virol 2006, 87: 2577-2581. 10.1099\/vir.0.81932-0","journal-title":"J Gen Virol"},{"key":"248_CR21","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1086\/432478","volume":"41","author":"DM Netski","year":"2005","unstructured":"Netski DM, Mosbruger T, Depla E, Maertens G, Ray SC, Hamilton RG, Roundtree S, Thomas DL, McKeating J, Cox A: Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis 2005, 41: 667-675. 10.1086\/432478","journal-title":"Clin Infect Dis"},{"key":"248_CR22","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1093\/infdis\/165.3.438","volume":"165","author":"AM Prince","year":"1992","unstructured":"Prince AM, Brotman B, Huima T, Pascual D, Jaffery M, Inchauspe G: Immunity in hepatitis C infection. J Infect Dis 1992, 165: 438-443.","journal-title":"J Infect Dis"},{"key":"248_CR23","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S0140-6736(94)91224-6","volume":"343","author":"ME Lai","year":"1994","unstructured":"Lai ME, Mazzoleni AP, Argiolu F, De Virgilis S, Balestrieri A, Purcell RH, Cao A, Farci P: Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 1994, 343: 388-390. 10.1016\/S0140-6736(94)91224-6","journal-title":"Lancet"},{"key":"248_CR24","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1126\/science.1279801","volume":"258","author":"P Farci","year":"1992","unstructured":"Farci P, Alter HJ, Govindarajan S, Wong DC, Engle R, Lesniewski RR, Mushahwar IK, Desai SM, Miller RH, Ogata N, et al.: Lack of protective immunity against reinfection with hepatitis C virus. Science 1992, 258: 135-140. 10.1126\/science.1279801","journal-title":"Science"},{"key":"248_CR25","doi-asserted-by":"publisher","first-page":"6875","DOI":"10.1128\/JVI.78.13.6875-6882.2004","volume":"78","author":"M Flint","year":"2004","unstructured":"Flint M, Logvinoff C, Rice CM, McKeating JA: Characterization of infectious retroviral pseudotype particles bearing hepatitis C virus glycoproteins. J Virol 2004, 78: 6875-6882. 10.1128\/JVI.78.13.6875-6882.2004","journal-title":"J Virol"},{"key":"248_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jviromet.2005.05.027","volume":"130","author":"O Eyal","year":"2005","unstructured":"Eyal O, Olshevsky U, Lustig S, Paran N, Halevy M, Schneider P, Zomber G, Fuchs P: Development of a tissue-culture-based enzyme-immunoassay method for the quantitation of anti-vaccinia-neutralizing antibodies in human sera. J Virol Methods 2005, 130: 15-21. 10.1016\/j.jviromet.2005.05.027","journal-title":"J Virol Methods"},{"key":"248_CR27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jim.2005.03.008","volume":"301","author":"S Wang","year":"2005","unstructured":"Wang S, Sakhatskyy P, Chou TH, Lu S: Assays for the assessment of neutralizing antibody activities against Severe Acute Respiratory Syndrome (SARS) associated coronavirus (SCV). J Immunol Methods 2005, 301: 21-30. 10.1016\/j.jim.2005.03.008","journal-title":"J Immunol Methods"},{"key":"248_CR28","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1743-422X-2-84","volume":"2","author":"E Zielinska","year":"2005","unstructured":"Zielinska E, Liu D, Wu HY, Quiroz J, Rappaport R, Yang DP: Development of an improved microneutralization assay for respiratory syncytial virus by automated plaque counting using imaging analysis. Virol J 2005, 2: 84. 10.1186\/1743-422X-2-84","journal-title":"Virol J"},{"key":"248_CR29","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0065-2776(01)77018-6","volume":"77","author":"PW Parren","year":"2001","unstructured":"Parren PW, Burton DR: The antiviral activity of antibodies in vitro and in vivo. Adv Immunol 2001, 77: 195-262.","journal-title":"Adv Immunol"},{"key":"248_CR30","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1365-2893.2005.00605.x","volume":"12","author":"C Payan","year":"2005","unstructured":"Payan C, Roudot-Thoraval F, Marcellin P, Bled N, Duverlie G, Fouchard-Hubert I, Trimoulet P, Couzigou P, Cointe D, Chaput C, et al.: Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. J Viral Hepat 2005, 12: 405-413. 10.1111\/j.1365-2893.2005.00605.x","journal-title":"J Viral Hepat"},{"key":"248_CR31","doi-asserted-by":"publisher","first-page":"5308","DOI":"10.1128\/JVI.02460-05","volume":"80","author":"G Koutsoudakis","year":"2006","unstructured":"Koutsoudakis G, Kaul A, Steinmann E, Kallis S, Lohmann V, Pietschmann T, Bartenschlager R: Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol 2006, 80: 5308-5320. 10.1128\/JVI.02460-05","journal-title":"J Virol"},{"key":"248_CR32","first-page":"3858","volume":"42","author":"H Nakabayashi","year":"1982","unstructured":"Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J: Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 1982, 42: 3858-3863.","journal-title":"Cancer Res"},{"key":"248_CR33","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1128\/JVI.80.6.2832-2841.2006","volume":"80","author":"Y Rouille","year":"2006","unstructured":"Rouille Y, Helle F, Delgrange D, Roingeard P, Voisset C, Blanchard E, Belouzard S, McKeating J, Patel AH, Maertens G, et al.: Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus. J Virol 2006, 80: 2832-2841. 10.1128\/JVI.80.6.2832-2841.2006","journal-title":"J Virol"},{"key":"248_CR34","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0166-0934(97)02184-8","volume":"65","author":"S Castelain","year":"1997","unstructured":"Castelain S, Khorsi H, Zawadzki P, Sueur JM, Capron JP, Eb F, Duverlie G: Direct blotting electrophoresis for sequencing and genotyping hepatitis C virus. J Virol Methods 1997, 65: 237-243. 10.1016\/S0166-0934(97)02184-8","journal-title":"J Virol Methods"},{"key":"248_CR35","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jviromet.2005.12.002","volume":"134","author":"NC Martin","year":"2006","unstructured":"Martin NC, Pardo J, Simmons M, Tjaden JA, Widjaja S, Marovich MA, Sun W, Porter KR, Burgess TH: An immunocytometric assay based on dengue infection via DC-SIGN permits rapid measurement of anti-dengue neutralizing antibodies. J Virol Methods 2006, 134: 74-85. 10.1016\/j.jviromet.2005.12.002","journal-title":"J Virol Methods"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1743-422X-4-35.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T07:35:30Z","timestamp":1630481730000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/1743-422X-4-35"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3,30]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["248"],"URL":"https:\/\/doi.org\/10.1186\/1743-422x-4-35","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,3,30]]},"assertion":[{"value":"26 January 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2007","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"35"}}